During this webinar, QIAGEN Chief Medical Officer Dr. Davide Manissero will discuss the role of multiplex respiratory PCR testing in the ongoing COVID-19 pandemic and how QIAGEN ramped up development efforts to be the first syndromic solution on the market. The importance of time to diagnosis and potential for co-infections as we approach the 2020-2021 influenza season will be discussed.
The development of rapid multiplex PCR tests enables the detection of almost all respiratory viruses in a few hours. These tests provide a deeper understanding of respiratory viruses’ epidemiology among children or adults, as well as community- or hospital-acquired infections. They also allow clinicians to consider viral etiology to improve isolation management, antibiotic use, or a patient’s length of stay.
While these tests offer clear benefits for some patient populations, labs looking to adopt rapid multiplex PCR testing must balance their costs against the impact on patient care.
In this webinar, Dr. Benoit Visseaux of Bichat Claude Bernard Hospital, a university hospital in Paris, shares his experience implementing multiplex PCR testing for respiratory viruses. He discusses the challenges of balancing costs with improved patient outcomes.
Modern PCR technologies are changing the workflow of medical microbiology laboratories, making it possible to get molecular test results within an hour instead of days to weeks. Smaller and cheaper analyzers also make multiplex PCR techniques possible for smaller laboratories without a molecular testing department.
Although the Ikazia hospital is one of the smaller hospitals in Rotterdam (360 beds), it has offered a “24/7” PCR service to its medical staff for 10 years, starting with molecular screening for methicillin-resistant Staphylococcus aureus in 2009. The hospital has expanded its portfolio in the last decade, and most recently, rolled out multiplex syndromic testing in 2018.
In this webinar, Dr. Michiel van Rijn speaks about the implementation of a rapid 24/7 PCR service in his hospital and the effects of this service on patient outcomes and clinical decision making strategies. In particular, he shares his experiences with DiagCORE syndromic testing and his expectation of further use of this technology in the future.
Acute respiratory tract infections are caused by a wide range of viral and bacterial pathogens and may share similar clinical presentations that make it difficult for physicians to diagnose based on symptoms alone. Syndromic testing with multiplex molecular panels offers clinical labs a way to quickly distinguish between a broad array of respiratory pathogens.
In this webinar, Dr. Steve Young of Tricore Reference Laboratories presents a new technology for multiplexed respiratory testing in acutely ill patients. He shares data demonstrating the capabilities of syndromic respiratory testing as well as his impressions on the ease of doing comprehensive syndromic testing using the QIAstat-Dx Analyzer.
As a fellow in a diagnostic lab, Dr. Utsav Pandey experiences firsthand the influx of respiratory testing during the flu season. He recently detailed how the lab utilizes multiplex testing on the QIAstat-Dx to address these requests.
In this recorded mini-session, hear about the lab’s QIAstat-Dx experience, including how the ability to view amplification plots and Ct values for pathogens can help provide additional information.
Watch the session highlights to hear about:
• Challenges diagnosing upper respiratory tract infections
• Syndromic testing and its potential clinical impact on patient management
• Dr. Pandey’s personal experience using the QIAstat-Dx